BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35588102)

  • 21. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
    Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
    Tian H; Tackmann NR; Jin A; Zheng J; Zhang Y
    J Biol Chem; 2017 Dec; 292(52):21614-21622. PubMed ID: 29123033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Auto-ubiquitination of Mdm2 enhances its substrate ubiquitin ligase activity.
    Ranaweera RS; Yang X
    J Biol Chem; 2013 Jun; 288(26):18939-46. PubMed ID: 23671280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.
    Meulmeester E; Pereg Y; Shiloh Y; Jochemsen AG
    Cell Cycle; 2005 Sep; 4(9):1166-70. PubMed ID: 16082221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of the p53 tumor suppressor pathway: the problems and promises of studying Mdm2's E3 ligase function.
    Clegg HV; Zhang Y
    Crit Rev Eukaryot Gene Expr; 2010; 20(1):77-86. PubMed ID: 20528739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p53 ubiquitination: Mdm2 and beyond.
    Brooks CL; Gu W
    Mol Cell; 2006 Feb; 21(3):307-15. PubMed ID: 16455486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mdm2 and MdmX partner to regulate p53.
    Wang X; Jiang X
    FEBS Lett; 2012 May; 586(10):1390-6. PubMed ID: 22673503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 Inhibits Axin-Induced p53 Activation Independently of its E3 Ligase Activity.
    He Y; Lian G; Lin S; Ye Z; Li Q
    PLoS One; 2013; 8(6):e67529. PubMed ID: 23826318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage.
    Cheng Q; Cross B; Li B; Chen L; Li Z; Chen J
    Mol Cell Biol; 2011 Dec; 31(24):4951-63. PubMed ID: 21986495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.
    Kawai H; Lopez-Pajares V; Kim MM; Wiederschain D; Yuan ZM
    Cancer Res; 2007 Jul; 67(13):6026-30. PubMed ID: 17616658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
    Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
    Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM4 enhances p53 stability by promoting an active conformation of the protein upon DNA damage.
    Di Conza G; Mancini F; Buttarelli M; Pontecorvi A; Trimarchi F; Moretti F
    Cell Cycle; 2012 Feb; 11(4):749-60. PubMed ID: 22374672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mdm2 links genotoxic stress and metabolism to p53.
    Wang Z; Li B
    Protein Cell; 2010 Dec; 1(12):1063-72. PubMed ID: 21213101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2.
    García-Cano J; Sánchez-Tena S; Sala-Gaston J; Figueras A; Viñals F; Bartrons R; Ventura F; Rosa JL
    Mol Oncol; 2020 Jan; 14(1):69-86. PubMed ID: 31665549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
    Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
    Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
    Herman AG; Hayano M; Poyurovsky MV; Shimada K; Skouta R; Prives C; Stockwell BR
    Cancer Discov; 2011 Sep; 1(4):312-25. PubMed ID: 22586610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.
    Shloush J; Vlassov JE; Engson I; Duan S; Saridakis V; Dhe-Paganon S; Raught B; Sheng Y; Arrowsmith CH
    J Biol Chem; 2011 Feb; 286(6):4796-808. PubMed ID: 21084285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice.
    Humpton TJ; Nomura K; Weber J; Magnussen HM; Hock AK; Nixon C; Dhayade S; Stevenson D; Huang DT; Strathdee D; Blyth K; Vousden KH
    Genes Dev; 2021 Jan; 35(1-2):117-132. PubMed ID: 33334825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.